ImmunoGen has earned a $6.5 million milestone from a breast cancer therapy program in development with Genentech. Three trials from T-DM1 are progressing. ImmunoGen garnered the money after Roche and Genentech launched a late-stage trial of T-DM1 as a second-line therapy for metastasized breast cancer which features HER-2. A separate trial to test the therapy as a third-line treatment for breast cancer is ahead of schedule, with enrollment wrapping up at the end of March. And Genentech is considering testing the drug as an adjuvant to prevent the recurrence of disease. ImmunoGen release